Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
BlossomHill Therapeutics, Inc.
Market Cap
$502.81M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$503.93M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
-2215.86%
5Y Avg
-1460.58%
Market Cap
$504.04M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
83.33%
Market Cap
$500.52M
Gross Margin
74.23%
TTM Avg
74.56%
3Y Avg
72.89%
5Y Avg
72.29%
Market Cap
$505.87M
Gross Margin
49.79%
TTM Avg
48.93%
3Y Avg
50.95%
5Y Avg
52.39%
Market Cap
$498.52M
Gross Margin
0.00%
TTM Avg
-3746.14%
3Y Avg
-1873.07%
5Y Avg
-1248.71%
Market Cap
$516.76M
Gross Margin
73.28%
TTM Avg
79.19%
3Y Avg
65.08%
5Y Avg
51.90%
Market Cap
$519.25M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $502.81M | 0.00% | 0.00% | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | 0.00% | 50.00% | -2215.86% | -1460.58% |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | 100.00% | 50.00% | 75.00% | 83.33% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.52M | 74.23% | 74.56% | 72.89% | 72.29% |
| 908 Devices Inc. (MASS)vs › | $505.87M | 49.79% | 48.93% | 50.95% | 52.39% |
| Oculis Holding AG (OCS)vs › | $498.52M | 0.00% | -3746.14% | -1873.07% | -1248.71% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 73.28% | 79.19% | 65.08% | 51.90% |
| Altimmune, Inc. (ALT)vs › | $519.25M | 100.00% | 100.00% | 100.00% | 31.77% |
| Evolus, Inc. (EOLS)vs › | $486.01M | 66.25% | 66.66% | 65.82% | 64.54% |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 74.83% | 73.30% | 73.96% | 75.53% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-03-31 | 0.00% |
